Highest-materiality recent filing
Nephros Q2 revenue record $6M (+36% YoY); net income $1.2M includes $0.6M tariff refund
Net revenue $6.0M (record), up 36% YoY; core programmatic revenue grew 27%.
Nephros Q1 net revenue up 7% to $5.2M; net income falls to $140K; tariffs hit margins
Net revenue $5.2M (+7% YoY); programmatic revenue up 23% YoY.
Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.
Net revenue $4.4M, up 36% YoY from $3.3M; net income $237k vs net loss $289k.
Nephros Q1 2025 revenue $4.9M (+38% YoY), net income $558K, adjusted EBITDA $667K
Net revenue $4.9M, up 38% from $3.5M in Q1 2024; core programmatic revenue grew 23%.
Nephros reports first annual net income; Q4 revenue up 19% YoY to $3.9M
Net income of $74K for FY2024 vs net loss of $1.6M in 2023; first annual profit in company history.
Nephros posts Q3 net income of $0.2M, first profitable quarter; revenue $3.5M
Net revenue $3.5M, down 6% YoY but up 8% from Q2 2024.
Nephros Q1 revenue down 5% to $3.5M; net loss narrows to $0.2M
Net revenue $3.5M, down 5% YoY, but programmatic (recurring non-ER) business grew 12% YoY.
Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M
Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.
Nephros Q2 2023 revenue $3.5M (+24% YoY); net loss narrows to $0.4M
Net revenue $3.5M, up 24% from $2.9M in Q2 2022.
Nephros appoints Robert Banks as President & CEO; Andy Astor remains interim CFO
Robert Banks named President & CEO effective after Q1 2023 10-Q filing; also appointed to Board.
Nephros preliminary Q1 net revenue $3.7M (+69% YoY); expects break-even cash flow from ops
Net revenue approximately $3.7 million for Q1 2023, a 69% increase over Q1 2022.
Nephros reports FY2022 net revenue $10M; net loss widens to $4.3M; subsidiary SRP winding down
Net revenue from continuing operations: $10.0M in FY2022 (-2% YoY); Q4 $2.6M (-6% YoY).
Nephros reports preliminary Q4 revenue of $2.6M, FY2022 revenue of $10.0M
Q4 2022 net revenue ~$2.6M, down 6% YoY but up 6% sequentially.
Nephros closes sale of Pathogen Detection Systems business to BWSI, LLC
Closing occurred Nov 15, 2022; BWSI made nominal cash payment and assumed certain liabilities.
Nephros Q3 net revenue $2.4M (-7% YoY); net loss widens to $1.3M; sells PDS business
Net revenue from continuing operations $2.4M, down 7% vs Q3 2021; net loss $1.3M vs $0.8M.
Nephros sells Pathogen Detection Systems business, reports prelim Q3 revenue ~$2.5M
Entered definitive agreement to sell Pathogen Detection Systems (PDS) business to BWSI; expected close mid-November 2022.
Nephros prelim Q2 revenue $2.9M, up 27% YoY; expects positive net cash flow in 12 months
Q2 2022 preliminary net revenue ~$2.9M, a 27% increase from $2.3M in Q2 2021.
First and only FDA-cleared device in the US to provide hemodiafiltration therapy to ESRD patients.
Nephros Q1 revenue falls 20% YoY to $2.2M; withdraws 2022 guidance
Net loss of $2.0M vs $0.5M in Q1 2021; adjusted EBITDA -$1.5M.
Nephros FY2021 revenue $10.4M (+22% YoY); net loss narrows to $3.9M
Full-year revenue $10.4M, up 22% from $8.6M in 2020; Q4 revenue $2.8M, up 18%.
Nephros reports record FY2021 revenue of $10.4M, guides FY2022 $13-13.5M
Preliminary FY2021 net revenue $10.4M (+21% YoY); Q4 revenue $2.8M (+18% YoY).
Nephros prelim Q3 2021 net revenue ~$2.6M (+24% YoY); YTD record $7.6M
Preliminary net revenue ~$2.6M for Q3 2021, up 24% YoY.
Net revenue $2.3M (+44% YoY); net loss improved 35% to $1.1M; adjusted EBITDA improved 46% to ($0.8M).
Nephros acquires GenArraytion for $1.2M in stock; gains PCR pathogen detection tech
Purchase price of $1.2M paid via 123,981 shares of Nephros common stock.
Preliminary Q2 2021 net revenue ~$2.2M, >40% year-over-year increase.
On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).
Nephros, Inc. (the “Company”) appointed Judy Krandel as its Chief Financial Officer, effective November 1, 2023.
On November 1, 2023, in connection with Ms. Krandel’s appointment as Chief Financial Officer, Andrew Astor resigned as the Company’s Chief Financial Officer.
Mr. Banks was also appointed to the Company’s Board of Directors as a Class III director as of the Effective Date.
On May 5, 2023, Nephros, Inc. (the “Company”) entered into an employment agreement with Robert Banks (the “Employment Agreement”) pursuant to which the Company appointed Mr. Banks as its President and Chief Executive Officer
On May 5, 2023, Andrew Astor resigned as the Company’s President and Chief Executive Officer and from the Company’s Board of Directors, effective as of the Effective Date.
On February 2, 2023, the Company’s Board of Directors appointed Alisa Lask to serve as a member of its Audit Committee, filling the vacancy created by Mr. Gwydir’s resignation.
On January 30, 2023, Thomas Gwydir resigned from the Board of Directors of Nephros, Inc. (the “Company”), effective February 1, 2023.
appointed Joseph Harris as a director of the Company.
On August 17, 2022, Wes Lobo, Chief Commercial Officer of Nephros, Inc. (the “Company”), notified the Company that he is resigning his employment with the Company, to be effective no later than September 30, 2022.
Max materiality 0.75 · Median 0.62 · Most common event earnings